Hepatocellular carcinoma outcomes based on indicated treatment strategy

Amy T. Rose, D. Michael Rose, C. Wright Pinson, J. Kelly Wright, Taylor Blair, Charles Blanke, Dominique Delbeke, J. P. Debelak, William C. Chapman

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) in Western populations historically has been associated with poor survival. In this study, we conducted a 7-year retrospective analysis of patients evaluated at our institution with HCC to determine the effects of newer treatment strategies on outcome. During the period of study, 117 patients [86 (74%) male; mean age, 59 years (range, 16- 85)] were evaluated with treatment as follows: surgical resection in 22 (19%), chemoembolization with or without systemic chemotherapy in 40 (35%), systemic treatment alone in 16 (13%), orthotopic liver transplantation in 8 (7%), and supportive care only in 31 (26%). Sixty-nine patients (59%) had documented cirrhosis, with hepatitis C being the most common cause in 27 of 69 (39%). In patients receiving no treatment, median survival was just under 3 months, with only two 1-year survivors. Patients with orthotopic liver transplantation had 1-, 2-, and 3-year survival rates of 87, 87, and 58 per cent compared with 69, 52, and 43 per cent in surgically resected patients. Survival after chemoembolization was 35, 20, and 11 per cent at 1, 2, and 3 years, whereas survival after systemic chemotherapy was 30 and 15 per cent at 1 and 2 years, respectively. One-year survival was improved in noncirrhotic patients compared with cirrhotics (47% vs 29%; P <0.05) but was no different in patients younger than 55 years compared with older patients (38% vs 38%). When possible, surgical treatment strategies offer superior survival.

Original languageEnglish (US)
Pages (from-to)1128-1135
Number of pages8
JournalAmerican Surgeon
Volume64
Issue number12
StatePublished - Dec 1998

Fingerprint

Hepatocellular Carcinoma
Survival
Therapeutics
Liver Transplantation
Drug Therapy
Hepatitis C
Survivors
Fibrosis
Survival Rate
Population

ASJC Scopus subject areas

  • Surgery

Cite this

Rose, A. T., Rose, D. M., Pinson, C. W., Wright, J. K., Blair, T., Blanke, C., ... Chapman, W. C. (1998). Hepatocellular carcinoma outcomes based on indicated treatment strategy. American Surgeon, 64(12), 1128-1135.

Hepatocellular carcinoma outcomes based on indicated treatment strategy. / Rose, Amy T.; Rose, D. Michael; Pinson, C. Wright; Wright, J. Kelly; Blair, Taylor; Blanke, Charles; Delbeke, Dominique; Debelak, J. P.; Chapman, William C.

In: American Surgeon, Vol. 64, No. 12, 12.1998, p. 1128-1135.

Research output: Contribution to journalArticle

Rose, AT, Rose, DM, Pinson, CW, Wright, JK, Blair, T, Blanke, C, Delbeke, D, Debelak, JP & Chapman, WC 1998, 'Hepatocellular carcinoma outcomes based on indicated treatment strategy', American Surgeon, vol. 64, no. 12, pp. 1128-1135.
Rose AT, Rose DM, Pinson CW, Wright JK, Blair T, Blanke C et al. Hepatocellular carcinoma outcomes based on indicated treatment strategy. American Surgeon. 1998 Dec;64(12):1128-1135.
Rose, Amy T. ; Rose, D. Michael ; Pinson, C. Wright ; Wright, J. Kelly ; Blair, Taylor ; Blanke, Charles ; Delbeke, Dominique ; Debelak, J. P. ; Chapman, William C. / Hepatocellular carcinoma outcomes based on indicated treatment strategy. In: American Surgeon. 1998 ; Vol. 64, No. 12. pp. 1128-1135.
@article{afe4978b5c9f44ae99da47d5bd3bb165,
title = "Hepatocellular carcinoma outcomes based on indicated treatment strategy",
abstract = "Hepatocellular carcinoma (HCC) in Western populations historically has been associated with poor survival. In this study, we conducted a 7-year retrospective analysis of patients evaluated at our institution with HCC to determine the effects of newer treatment strategies on outcome. During the period of study, 117 patients [86 (74{\%}) male; mean age, 59 years (range, 16- 85)] were evaluated with treatment as follows: surgical resection in 22 (19{\%}), chemoembolization with or without systemic chemotherapy in 40 (35{\%}), systemic treatment alone in 16 (13{\%}), orthotopic liver transplantation in 8 (7{\%}), and supportive care only in 31 (26{\%}). Sixty-nine patients (59{\%}) had documented cirrhosis, with hepatitis C being the most common cause in 27 of 69 (39{\%}). In patients receiving no treatment, median survival was just under 3 months, with only two 1-year survivors. Patients with orthotopic liver transplantation had 1-, 2-, and 3-year survival rates of 87, 87, and 58 per cent compared with 69, 52, and 43 per cent in surgically resected patients. Survival after chemoembolization was 35, 20, and 11 per cent at 1, 2, and 3 years, whereas survival after systemic chemotherapy was 30 and 15 per cent at 1 and 2 years, respectively. One-year survival was improved in noncirrhotic patients compared with cirrhotics (47{\%} vs 29{\%}; P <0.05) but was no different in patients younger than 55 years compared with older patients (38{\%} vs 38{\%}). When possible, surgical treatment strategies offer superior survival.",
author = "Rose, {Amy T.} and Rose, {D. Michael} and Pinson, {C. Wright} and Wright, {J. Kelly} and Taylor Blair and Charles Blanke and Dominique Delbeke and Debelak, {J. P.} and Chapman, {William C.}",
year = "1998",
month = "12",
language = "English (US)",
volume = "64",
pages = "1128--1135",
journal = "The American surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "12",

}

TY - JOUR

T1 - Hepatocellular carcinoma outcomes based on indicated treatment strategy

AU - Rose, Amy T.

AU - Rose, D. Michael

AU - Pinson, C. Wright

AU - Wright, J. Kelly

AU - Blair, Taylor

AU - Blanke, Charles

AU - Delbeke, Dominique

AU - Debelak, J. P.

AU - Chapman, William C.

PY - 1998/12

Y1 - 1998/12

N2 - Hepatocellular carcinoma (HCC) in Western populations historically has been associated with poor survival. In this study, we conducted a 7-year retrospective analysis of patients evaluated at our institution with HCC to determine the effects of newer treatment strategies on outcome. During the period of study, 117 patients [86 (74%) male; mean age, 59 years (range, 16- 85)] were evaluated with treatment as follows: surgical resection in 22 (19%), chemoembolization with or without systemic chemotherapy in 40 (35%), systemic treatment alone in 16 (13%), orthotopic liver transplantation in 8 (7%), and supportive care only in 31 (26%). Sixty-nine patients (59%) had documented cirrhosis, with hepatitis C being the most common cause in 27 of 69 (39%). In patients receiving no treatment, median survival was just under 3 months, with only two 1-year survivors. Patients with orthotopic liver transplantation had 1-, 2-, and 3-year survival rates of 87, 87, and 58 per cent compared with 69, 52, and 43 per cent in surgically resected patients. Survival after chemoembolization was 35, 20, and 11 per cent at 1, 2, and 3 years, whereas survival after systemic chemotherapy was 30 and 15 per cent at 1 and 2 years, respectively. One-year survival was improved in noncirrhotic patients compared with cirrhotics (47% vs 29%; P <0.05) but was no different in patients younger than 55 years compared with older patients (38% vs 38%). When possible, surgical treatment strategies offer superior survival.

AB - Hepatocellular carcinoma (HCC) in Western populations historically has been associated with poor survival. In this study, we conducted a 7-year retrospective analysis of patients evaluated at our institution with HCC to determine the effects of newer treatment strategies on outcome. During the period of study, 117 patients [86 (74%) male; mean age, 59 years (range, 16- 85)] were evaluated with treatment as follows: surgical resection in 22 (19%), chemoembolization with or without systemic chemotherapy in 40 (35%), systemic treatment alone in 16 (13%), orthotopic liver transplantation in 8 (7%), and supportive care only in 31 (26%). Sixty-nine patients (59%) had documented cirrhosis, with hepatitis C being the most common cause in 27 of 69 (39%). In patients receiving no treatment, median survival was just under 3 months, with only two 1-year survivors. Patients with orthotopic liver transplantation had 1-, 2-, and 3-year survival rates of 87, 87, and 58 per cent compared with 69, 52, and 43 per cent in surgically resected patients. Survival after chemoembolization was 35, 20, and 11 per cent at 1, 2, and 3 years, whereas survival after systemic chemotherapy was 30 and 15 per cent at 1 and 2 years, respectively. One-year survival was improved in noncirrhotic patients compared with cirrhotics (47% vs 29%; P <0.05) but was no different in patients younger than 55 years compared with older patients (38% vs 38%). When possible, surgical treatment strategies offer superior survival.

UR - http://www.scopus.com/inward/record.url?scp=0031790971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031790971&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 1128

EP - 1135

JO - The American surgeon

JF - The American surgeon

SN - 0003-1348

IS - 12

ER -